Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of GR2002 in Healthy Chinese Volunteers
NCT05954611Phase 1Completed
- Sponsor
- Zhixiang Jintai
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing GR2002 injection with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events at 85 days. Started Jun 2023; status: completed.
02
Drugs
GR2002
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05954611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954611.